The enteroinsular axis revisited. A novel role for an incretin.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

5 citing papers in PubMed.

1. Glucagon-like peptide-1 receptor agonists for type 2 diabetes: A rational drug development.Journal of diabetes investigation · 2019
   Review
2. DPP-4 Inhibition and the Path to Clinical Proof.Frontiers in endocrinology · 2019
   Review
3. Attenuated GLP-1 secretion in obesity: cause or consequence?Gut · 1996
   Article
4. Glucagon-like-peptide-1 (7-36) amide improves glucose sensitivity in beta-cells of NOD mice.Acta diabetologica · 1996
   Article
5. In vivo expression of mutant preproendothelins: hierarchy of processing events but no strict requirement of Trp-Val at the processing site.Proceedings of the National Academy of Sciences of the United States of America · 1993
   Article

Corrections and comments

• Comment on
  Antidiabetogenic effect of glucagon-like peptide-1 (7-36)amide in normal subjects and patients with diabetes mellitus.1992

Authors and funding

2 authors.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as